Avidity biosciences reports fourth quarter 2024 financial results and recent highlights

Building on success across its three clinical programs, avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 m ajor milestones anticipated for each rare neuromuscular program in 2025,  including preparing for avidity's first bla submission  commercial preparations well underway in anticipation of three potential successive product launches for dmd, dm1 and fshd starting in 2026 phase 1/2 explore44 ® top-line del-zota data to be presented at the 2025 muscular dystrophy association (mda) clinical and scientific conference in dallas, texas san diego , feb. 27, 2025 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™) to profoundly improve people's lives, today reported financial results for the fourth quarter ended december 31, 2024, highlighting recent progress and reiterating 2025 catalysts for its three clinical programs. "successful readouts from our three clinical-stage programs in 2024 demonstrate the consistent and reproducible data of our aoc platform.
RNA Ratings Summary
RNA Quant Ranking